Seo J, Shin S, Kim S, Kim S, Lee M, Song K
Int J Mol Sci. 2023; 24(4).
PMID: 36834714
PMC: 9966410.
DOI: 10.3390/ijms24043297.
Wada T, Ichikawa C, Takeuchi M, Matsui F, Matsumoto F, Ida S
Clin Pediatr Endocrinol. 2022; 31(3):144-151.
PMID: 35928389
PMC: 9297171.
DOI: 10.1297/cpe.2022-0025.
Maria Guadalupe O, Katy S, Charmina A, Vihko P, Marta M
Front Genet. 2022; 12:794476.
PMID: 35154247
PMC: 8829113.
DOI: 10.3389/fgene.2021.794476.
Alswailem M, Alzahrani O, Alghofaili L, Qasem E, Almohanaa M, Alsagheir A
Endocrine. 2018; 63(2):361-368.
PMID: 30269266
DOI: 10.1007/s12020-018-1767-1.
Agis-Balboa R, Guidotti A, Pinna G
Psychopharmacology (Berl). 2014; 231(17):3569-80.
PMID: 24781515
PMC: 6223254.
DOI: 10.1007/s00213-014-3567-5.
Polymorphisms of HPC2/ELAC2 and SRD5A2 (5α-Reductase Type II) Genes in Prostate Cancer.
Izmirli M, Arikan B, Bayazit Y, Alptekin D
Balkan J Med Genet. 2013; 14(1):31-6.
PMID: 24052700
PMC: 3776688.
DOI: 10.2478/v10034-011-0015-2.
Discovery of a novel hybrid from finasteride and epristeride as 5α-reductase inhibitor.
Yao Z, Xu Y, Zhang M, Jiang S, Nicklaus M, Liao C
Bioorg Med Chem Lett. 2010; 21(1):475-8.
PMID: 21094046
PMC: 7296779.
DOI: 10.1016/j.bmcl.2010.10.112.
5α-Reductase Isozymes in the Prostate.
Zhu Y, Sun G
J Med Sci. 2008; 25(1):1-12.
PMID: 18483578
PMC: 2386416.
Novel compound heterozygous mutations in the SRD5A2 gene from 46,XY infants with ambiguous external genitalia.
Vilchis F, Valdez E, Ramos L, Garcia R, Gomez R, Chavez B
J Hum Genet. 2008; 53(5):401-406.
PMID: 18350250
DOI: 10.1007/s10038-008-0274-2.
SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness.
Neslund-Dudas C, Bock C, Monaghan K, Nock N, Yang J, Rundle A
Prostate. 2007; 67(15):1654-63.
PMID: 17823934
PMC: 2132439.
DOI: 10.1002/pros.20625.
Molecular Basis of Steroid Action in the Prostate.
Zhu Y
Cellscience. 2006; 1(4):27-55.
PMID: 16971966
PMC: 1564164.
DOI: 10.1901/jaba.2005.1-27.
Semiquantitative RT-PCR method coupled to capillary electrophoresis to study 5alpha-reductase mRNA isozymes in rat ventral prostate in different androgen status.
Torres J, Gomez-Capilla J, Ruiz E, Ortega E
Mol Cell Biochem. 2003; 250(1-2):125-30.
PMID: 12962150
DOI: 10.1023/a:1024902419502.
A49T, V89L and TA repeat polymorphisms of steroid 5alpha-reductase type II and breast cancer risk in Japanese women.
Yang C, Hamajima N, Iwata H, Saito T, Matsuo K, Hirose K
Breast Cancer Res. 2002; 4(4):R8.
PMID: 12100746
PMC: 116722.
DOI: 10.1186/bcr445.
Codon 89 polymorphism in the human 5 alpha-reductase gene in primary breast cancer.
Scorilas A, Bharaj B, Giai M, Diamandis E
Br J Cancer. 2001; 84(6):760-7.
PMID: 11259089
PMC: 2363825.
DOI: 10.1054/bjoc.2000.1681.
The mouse Clock locus: sequence and comparative analysis of 204 kb from mouse chromosome 5.
Wilsbacher L, Sangoram A, Antoch M, Takahashi J
Genome Res. 2000; 10(12):1928-40.
PMID: 11116088
PMC: 313079.
DOI: 10.1101/gr.10.12.1928.
Effect of finasteride in idiopathic hirsutism.
Faloia E, Filipponi S, Mancini V, Di Marco S, Mantero F
J Endocrinol Invest. 1998; 21(10):694-8.
PMID: 9854686
DOI: 10.1007/BF03350800.
Endocrine and adrenergic pharmacological intervention in diseases of the prostate.
Rane A
Br J Clin Pharmacol. 1998; 45(4):329-37.
PMID: 9578179
PMC: 1873965.
DOI: 10.1046/j.1365-2125.1998.t01-1-00688.x.
Male pseudohermaphroditism resulting from a novel mutation in the human steroid 5 alpha-reductase type 2 gene (SRD5A2).
Anwar R, Gilbey S, New J, Markham A
Mol Pathol. 1997; 50(1):51-2.
PMID: 9208814
PMC: 379579.
DOI: 10.1136/mp.50.1.51.
Molecular genetic analysis and human chorionic gonadotropin stimulation tests in the diagnosis of prepubertal patients with partial 5 alpha-reductase deficiency.
Hiort O, Willenbring H, Albers N, Hecker W, Engert J, Dibbelt L
Eur J Pediatr. 1996; 155(6):445-51.
PMID: 8789759
DOI: 10.1007/BF01955179.
New nucleotide sequence data on the EMBL File Server.
Nucleic Acids Res. 1992; 20(24):6749-67.
PMID: 1480500
PMC: 334604.
DOI: 10.1093/nar/20.24.6749.